article thumbnail

The MEK effect on cancer — a slow and steady approach to drug resistance

PharmaVoice

You just want to slash it, rip it out or attack it like an enemy target,” said Benjamin Zeskind, co-founder, CEO and president of Immuneering Corporation. To overcome that hurdle, Immuneering is testing an approach that slows cancer down rather than rushing to destroy it.

article thumbnail

Glenmark launches TEVIMBRA in India for treatment of advanced lung and oesophageal cancer

Express Pharma

This marks Glenmark’s entry into the field of immune-oncology within the country. It is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Alvotech and Dr. Reddy’s partner for Keytruda biosimilar

Pharmaceutical Business Review

Keytruda originally developed by MSD, engages with the body’s immune system rather than traditional treatments like chemotherapy or radiation therapy. Both companies retain rights to commercialise the product globally under certain conditions outlined in their agreement.

article thumbnail

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacy Times

Further, the incidence, severity, and kinetics of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome with CD20 × CD3 TCEs may vary depending on the B-cell lymphoma subtype and the combination partners used, which is a notable consideration for oncology pharmacists when operationalizing these therapies.

article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic.

article thumbnail

Pharmacies Need Strategies to Improve Health Care Access

Pharmacy Times

Wick, MBA, RPh, FASCP Key Takeaways Pharmacists can address SDOH by providing patient-centered care, promoting immunizations, and offering point-of-care testing to improve health outcomes. Offering and promoting immunizations and point-of-care testing are 2 proven ways to address SDOH.

article thumbnail

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Pharmacy Times

Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. N Engl J Med. 2019;380:2020-2030. Subscribe Now!